Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 9/20 | 0.58 |
| ▸ | IL1RN | P18510 | 9/20 | 0.57 |
| ▸ | ECE1 | P42892 | 6/20 | 0.56 |
| ▸ | ERAP1 | Q9NZ08 | 3/20 | 0.55 |
| ▸ | MMP2 | P08253 | 4/20 | 0.55 |
| ▸ | MMP1 | P03956 | 2/20 | 0.55 |
| ▸ | MMP9 | P14780 | 2/20 | 0.55 |
| ▸ | MMP8 | P22894 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28081225 | 0.91 | ECE1 (0.56) | ERAP2ECE1MMP2MMP1MMP9 | |
| SCHEMBL30051783 | 0.86 | ECE1 (0.70) | ERAP2IL1RNECE1ERAP1MMP2 | |
| SCHEMBL4959976 | 0.86 | ERAP2 (0.75) | ERAP2IL1RNECE1ERAP1 | |
| SCHEMBL4959992 | 0.86 | ERAP2 (0.75) | ERAP2IL1RNECE1ERAP1 | |
| SCHEMBL9822631 | 0.86 | ECE1 (0.70) | ERAP2IL1RNECE1ERAP1MMP2 | |
| SCHEMBL29380143 | 0.84 | ERAP2 (0.69) | ERAP2IL1RNECE1ERAP1 | |
| SCHEMBL29380319 | 0.84 | ERAP2 (0.64) | ERAP2IL1RNECE1ERAP1MMP2 | |
| SCHEMBL2192238 | 0.83 | KISS1R (0.57) | ERAP2IL1RNECE1ERAP1MMP2 | |
| SCHEMBL3979342 | 0.82 | ERAP2 (0.62) | ERAP2IL1RNECE1ERAP1MMP2 | |
| SCHEMBL30051087 | 0.82 | ACE (0.75) | ERAP2ECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | ERAP2 638/4885IL1RN 546/4885ECE1 1503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.